On May 22, 2020, Diversigen, an OraSure Technologies subsidiary, announced that Nom Nom had selected Diversigen as their preferred provider for metagenomics and microbiome sequencing and analysis services. Diversigen will also serve as Nom Nom’s central lab for the generation of high quality microbiome data.

Nom Nom is dedicated to research and data analysis to enable continued improvement of the health of all pets. The company has published multiple peer-reviewed studies on the pet microbiome (“gut health”) including one of the largest pet microbiome studies to date in which scientists analyzed and characterized the bacteria living in the guts of 238 pets in an effort to better understand how these microbes affect pet health. Ongoing efforts are aimed at evaluating the intersection of nutrition, microbiome, and common clinical conditions such as allergic diseases and obesity in pets.

The selection of Diversigen will allow Nom Nom to take advantage of Diversigen’s science-driven high quality CLIA customized solutions for metagenomics sequencing, bioinformatics, and statistical analysis for the study of the microbiome. Diversigen has a strong track record of supporting microbiome-focused clinical trials for big pharma customers, as well as thought-leading microbiome-focused biotech companies. In addition, Diversigen offers unparalleled scientific bench strength to define and meet the evolving microbiome arena with experts representing over a century of microbiome experience, over 300 scientific publications with more than 100,000 citations.